The role of TGFB1 gene polymorphisms in the development of post-transplant complications and optimization of calcineurin inhibitor dosing in solid organ transplant recipients: a literature review
Sep 2026· Russian Journal of Transplantology and Artificial Organs· 0 citations· 44 references
TL;DR
Current evidence regarding the role of TGFB1 gene polymorphisms in the development of post-transplant complications and their potential impact on calcineurin inhibitor dosing are analyzed to optimize immunosuppressive therapy in solid organ transplant recipients.
Abstract
Personalization of immunosuppressive therapy based on the recipient’s genetic profile remains a major challenge in transplant medicine, with important implications for reducing adverse effects associated with immunosuppressive drugs. Optimization of immunosuppressive regimens is largely focused on determining the appropriate dose of the calcineurin inhibitor tacrolimus (Tac), which serves as a key component of maintenance immunosuppressive therapy. A promising approach to this challenge is the identification of novel biomarkers associated with Тac response, among which transforming growth factor-β1 (TGF-β1), a key immunoregulatory cytokine, has attracted considerable attention. It has been established that the development of post-transplant complications, such as graft rejection, graft fibrosis, infectious complications, and nephrotoxicity, is associated with TGF-β1 expression levels. TGF-β1 production in the body is regulated by multiple factors, including genetic polymorphisms in the TGFB1 gene encoding this cytokine. This review analyzes current evidence regarding the role of TGFB1 gene polymorphisms in the development of post-transplant complications and their potential impact on calcineurin inhibitor dosing to optimize immunosuppressive therapy in solid organ transplant recipients.
A reduction in epithelial cell height was observed, along with increased apoptosis of cells in the apical surface of the jejunal villi, as well as changes in the immunoexpression levels of intercellular tight and adhesion junction proteins.
K. Szumilas, A. Wilk, K. Misiakiewicz-Has et al.· Medical Studies· 0 citations
Among 14 cytokines, IL-12p40 and IL-18 emerged as divergent signatures, both were elevated in patients who later developed severe fibrosing cGvHD, but their clinical associations differed markedly.
Salim Oulghazi, L. Alasfar, Mark E. Robinson et al.· Haematologica· 0 citations
The progressive increase in transplant activity is expected to increase the incidence of post-transplant complications, particularly post-transplant diabetes mellitus (PTDM). This review analyzes the epidemiology, risk factors, and key mechanisms for the development of this complication, such as immunosuppressive thera...
M. K. Vagabov, M. Shamkhalova, I. Dmitriev et al.· Diabetes mellitus· 0 citations
Background/Objectives: Long-term immunosuppressive therapy administered to solid organ transplant recipients may induce adverse effects in various tissues, including the gastrointestinal tract. The aim of the present study was to evaluate the influence of prolonged treatment with calcineurin inhibitor (CNI)-based tripl...
K. Szumilas, A. Wilk, P. Szumilas et al.· Biomedicines· 0 citations
IgA nephropathy (IgAN) is the most common primary chronic glomerulonephritis worldwide and a major cause of kidney failure requiring kidney replacement therapy. Current evidence indicates that its prognosis is considerably worse than previously assumed, while the proteinuria threshold associated with unfavorable outcom...
M. Zubkin, N. F. Frolova, V. I. Chervinko et al.· Nephrology and Dialysis· 0 citations
A post-marketing surveillance investigation comparing TGlobulin25 with the originator product regarding efficacy and safety in adult kidney transplant recipients found no statistically significant differences in major efficacy and safety outcomes.
M. Shafiekhani, Mohammad Amin Jafarzadeh, F. Shahabinezhad et al.· Iranian Journal of Medical S...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.